JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furlan, V.
Right arrow Articles by Taburet, A.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furlan, V.
Right arrow Articles by Taburet, A.-M.

Vol. 289, Issue 2, 1169-1175, May 1999

Glucuronidation of Drugs by Hepatic Microsomes Derived from Healthy and Cirrhotic Human Livers1

Valerie Furlan, Sylvie Demirdjian, Olivier Bourdon, Jacques Magdalou and Anne-Marie Taburet

Department of Clinical Pharmacy, Bicêtre Hospital, Assistance Publique, Hôpitaux de Paris, Paris, France (V.F., S.D., O.B., A.-M.T.); and School of Medicine, UMR 7561, Centre National de la Recherche Scientifique-University Henri Poincaré, Nancy I, Nancy, France (J.M.)

Pharmacokinetic studies demonstrated that the decrease in drug biotransformation in hepatic failure depends on the metabolic pathways involved. To test whether glucuronidation reactions supported by UDP-glucuronosyltransferases are differentially affected in such conditions, we investigated the in vitro glucuronidation of four selected drugs and xenobiotics (zidovudine, oxazepam, lamotrigine, and umbelliferone) by using microsomes from human healthy and unhealthy (cirrhosis, hepatitis) livers as enzyme sources. Theses substances are glucuronidated by several UDP-glucuronosyltransferase isoforms. Lidocaine N-deethylation activity measured concomitantly was used as a positive control, because the inhibition of this reaction in patients with hepatic diseases is well documented. The metabolic clearances of zidovudine and lidocaine were decreased significantly in liver cirrhosis (0.17 versus 0.37 µl/min/mg protein and 0.40 versus 2.73 µl/min/mg protein, respectively) as a consequence of a decrease of their corresponding Vmax of metabolism. By contrast, the metabolic clearances of oxazepam, umbelliferone, and lamotrigine glucuronidation remained unchanged. Previous studies reported that the in vivo oral clearances of zidovudine and lidocaine were decreased by 70% and 60%, respectively, in cirrhotic livers, whereas those of lamotrigine and oxazepam were not affected. Consequently, it is likely that the in vitro metabolic data, which support the in vivo results, therefore could contribute to reasonably predict the level of impairment of hepatic clearance in patients with liver cirrhosis.

0022-3565/99/2892-1169$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Iwamoto, W. D. Hanley, A. S. Petry, E. J. Friedman, J. T. Kost, S. A. Breidinger, K. C. Lasseter, R. Robson, N. M. Lunde, L. A. Wenning, et al.
Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1747 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball
DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. Ghosheh and E. M. Hawes
Microsomal N-Glucuronidation of Nicotine and Cotinine: Human Hepatic Interindividual, Human Intertissue, and Interspecies Hepatic Variation
Drug Metab. Dispos., December 1, 2002; 30(12): 1478 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Kumar, K. Samuel, R. Subramanian, M. P. Braun, R. A. Stearns, S.-H. L. Chiu, D. C. Evans, and T. A. Baillie
Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 969 - 978.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Toide, Y. Takahashi, H. Yamazaki, Y. Terauchi, T. Fujii, A. Parkinson, and T. Kamataki
Hepatocyte Nuclear Factor-1alpha Is a Causal Factor Responsible for Interindividual Differences in the Expression of UDP-Glucuronosyltransferase 2B7 mRNA in Human Livers
Drug Metab. Dispos., June 1, 2002; 30(6): 613 - 615.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C P Strassburg, A Strassburg, S Kneip, A Barut, R H Tukey, B Rodeck, and M P Manns
Developmental aspects of human hepatic drug glucuronidation in young children and adults
Gut, February 1, 2002; 50(2): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. Ghosheh, S. C. Vashishtha, and E. M. Hawes
Formation of the Quaternary Ammonium-Linked Glucuronide of Nicotine in Human Liver Microsomes: Identification and Stereoselectivity in the Kinetics
Drug Metab. Dispos., December 1, 2001; 29(12): 1525 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. C. Vashishtha, E. M. Hawes, G. McKay, and D. J. McCann
Quaternary Ammonium-Linked Glucuronidation of 1-Substituted Imidazoles: Studies of Human UDP-Glucuronosyltransferases Involved and Substrate Specificities
Drug Metab. Dispos., October 1, 2001; 29(10): 1290 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. N. Melgert, P. Olinga, B. Weert, M. J. H. Slooff, D. K. F. Meijer, K. Poelstra, and G. M. M. Groothuis
Cellular Distribution and Handling of Liver-Targeting Preparations in Human Livers Studied by a Liver Lobe Perfusion
Drug Metab. Dispos., June 1, 2001; 29(6): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. B. Andersson, H. Sjöberg, K.-J. Hoffmann, A. R. Boobis, P. Watts, R. J. Edwards, B. G. Lake, R. J. Price, A. B. Renwick, M. J. Gómez-Lechón, et al.
An Assessment of Human Liver-Derived in Vitro Systems to Predict the in Vivo Metabolism and Clearance of Almokalant
Drug Metab. Dispos., April 13, 2001; 29(5): 712 - 720.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
B. N. Melgert, P. Olinga, B. Weert, M. J. H. Slooff, D. K. F. Meijer, K. Poelstra, and G. M. M. Groothuis
Cellular Distribution and Handling of Liver-Targeting Preparations in Human Livers Studied by a Liver Lobe Perfusion
Drug Metab. Dispos., April 1, 2001; 29(4): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Ekins and R. S. Obach
Three-Dimensional Quantitative Structure Activity Relationship Computational Approaches for Prediction of Human In Vitro Intrinsic Clearance
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 463 - 473.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
S. C. Vashishtha, E. M. Hawes, G. McKay, and D. J. McCann
Synthesis and Identification of the Quaternary Ammonium-Linked Glucuronide of 1-Phenylimidazole in Human Liver Microsomes and Investigation of the Human UDP-Glucuronosyltransferases Involved
Drug Metab. Dispos., September 1, 2000; 28(9): 1009 - 1013.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.